52 related articles for article (PubMed ID: 28151059)
1. The Synergistic Effect of TNFα -308 G/A and TGFβ1 -509 C/T Polymorphisms on Hepatic Fibrosis Progression in Hepatitis C Virus Genotype 4 Patients.
Bader El Din NG; Farouk S; El-Shenawy R; Elhady MM; Ibrahim MK; Dawood RM; Salem AM; El Awady MK
Viral Immunol; 2017 Mar; 30(2):127-135. PubMed ID: 28151059
[TBL] [Abstract][Full Text] [Related]
2. Influence of polymorphisms in TNF-α and IL1β on susceptibility to alcohol induced liver diseases and therapeutic potential of miR-124-3p impeding TNF-α/IL1β mediated multi-cellular signaling in liver microenvironment.
Dasgupta D; Ghosh S; Dey I; Majumdar S; Chowdhury S; Das S; Banerjee S; Saha M; Ghosh A; Roy N; Manna A; Ray S; Agarwal S; Bhaumik P; Datta S; Chowdhury A; Banerjee S
Front Immunol; 2023; 14():1241755. PubMed ID: 38146363
[TBL] [Abstract][Full Text] [Related]
3. Influence of cytokine and ICAM-1 gene polymorphisms on susceptibility to chronic pancreatitis.
Howell WM; Pead PJ; Shek FW; Rose-Zerilli MJ; Armstrong T; Johnson CD; Fine DR; Iredale JP; Bateman AC
J Clin Pathol; 2005 Jun; 58(6):595-9. PubMed ID: 15917409
[TBL] [Abstract][Full Text] [Related]
4. Effects of transforming growth factor beta1 expression in a rat colon carcinoma: growth inhibition, leukocyte infiltration and production of interleukin-10 and tumor necrosis factor alpha.
Schiött A; Johansson AC; Widegren B; Sjögren HO; Lindvall M
Cancer Immunol Immunother; 2000 Jan; 48(10):579-87. PubMed ID: 10630310
[TBL] [Abstract][Full Text] [Related]
5. Sex hormone pathway gene polymorphisms are associated with risk of advanced hepatitis C-related liver disease in males.
White DL; Liu Y; Garcia J; El-Serag HB; Jiao L; Tsavachidis S; Franco LM; Lee JS; Tavakoli-Tabasi S; Moore D; Goldman R; Kuzniarek J; Ramsey DJ; Kanwal F; Marcelli M
Int J Mol Epidemiol Genet; 2014; 5(3):164-76. PubMed ID: 25379136
[TBL] [Abstract][Full Text] [Related]
6. GOAT rs10096097 and CREB1 rs6740584 single nucleotide polymorphisms are associated with type 2 diabetes mellitus in Egyptians.
Shahin NN; Shaker OG; Mahmoud MO
Arch Pharm (Weinheim); 2024 May; ():e2400011. PubMed ID: 38713912
[TBL] [Abstract][Full Text] [Related]
7. Complement factor 3 among children with hepatitis A: Assessment of bilirubin levels.
Lin W; Zhang J; Zhang J; Geng N; Ubuli-Aishan M; Wei X
J Pak Med Assoc; 2018 Jan; 68(1):21-27. PubMed ID: 29371712
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of the inactivated hepatitis A vaccine in children with juvenile idiopathic arthritis on methotrexate treatment: a matched case-control study.
Maritsi DN; Coffin SE; Argyri I; Vartzelis G; Spyridis N; Tsolia MN
Clin Exp Rheumatol; 2017; 35(4):711-715. PubMed ID: 28721859
[TBL] [Abstract][Full Text] [Related]
9. Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection.
Hogan JJ; Lim MA; Palmer MB; Bloom RD; Chung RT; Sise ME
Hepatology; 2017 Aug; 66(2):658-660. PubMed ID: 28211090
[No Abstract] [Full Text] [Related]
10. Sofosbuvir in the treatment of early HCV infection in HIV-infected men.
El Sayed A; Barbati ZR; Turner SS; Foster AL; Morey T; Dieterich DT; Fierer DS;
HIV Clin Trials; 2017 Mar; 18(2):60-66. PubMed ID: 28183221
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting.
Bach TA; Zaiken K
Am J Health Syst Pharm; 2017 Mar; 74(5 Supplement 1):S1-S9. PubMed ID: 28213381
[TBL] [Abstract][Full Text] [Related]
12. Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients.
Shaker OG; Senousy MA
J Viral Hepat; 2017 Aug; 24(8):636-644. PubMed ID: 28211229
[TBL] [Abstract][Full Text] [Related]
13. Novel emerging treatments for hepatitis C infection: a fast-moving pipeline.
Kardashian AA; Pockros PJ
Therap Adv Gastroenterol; 2017 Feb; 10(2):277-282. PubMed ID: 28203284
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.
Bourgeois S; Van Vlierberghe H; Moreno C; Orlent H; Nevens F; Arastéh K; Horsmans Y; Schattenberg JM; Buggisch P; Francque S; Vijgen L; Kakuda TN; Hoeben E; Luo D; Vandebosch A; Jacquemyn B; Van Remoortere P; Verloes R
BMC Gastroenterol; 2017 Feb; 17(1):26. PubMed ID: 28187751
[TBL] [Abstract][Full Text] [Related]
16. Point -of -care testing (POCT) in molecular diagnostics: Performance evaluation of GeneXpert HCV RNA test in diagnosing and monitoring of HCV infection.
Gupta E; Agarwala P; Kumar G; Maiwall R; Sarin SK
J Clin Virol; 2017 Mar; 88():46-51. PubMed ID: 28160728
[TBL] [Abstract][Full Text] [Related]
17. Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanism.
Lougiakis N; Frakolaki E; Karmou P; Pouli N; Marakos P; Madan V; Bartenschlager R; Vassilaki N
Chem Biol Drug Des; 2017 Sep; 90(3):352-367. PubMed ID: 28245093
[TBL] [Abstract][Full Text] [Related]
18. Human embryonic stem cell-derived hepatoblasts are an optimal lineage stage for hepatitis C virus infection.
Yan F; Wang Y; Zhang W; Chang M; He Z; Xu J; Shang C; Chen T; Liu J; Wang X; Pei X; Wang Y
Hepatology; 2017 Sep; 66(3):717-735. PubMed ID: 28236326
[TBL] [Abstract][Full Text] [Related]
19. Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1.
El-Diwany R; Cohen VJ; Mankowski MC; Wasilewski LN; Brady JK; Snider AE; Osburn WO; Murrell B; Ray SC; Bailey JR
PLoS Pathog; 2017 Feb; 13(2):e1006235. PubMed ID: 28235087
[TBL] [Abstract][Full Text] [Related]
20. HCV Antiviral Therapy in Liver Transplant Candidates and Recipients With Renal Insufficiency.
Verna EC; Brown RS
Transplantation; 2017 May; 101(5):924-932. PubMed ID: 28212220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
